VIVS

VivoSim Labs, Inc. Common Stock
VIVS
Market cap $3.11M

1.73 USD

-0.13

6.99%

At close Apr 28, 4:00 PM EDT

1 day

-6.99%

5 days

1.76%

1 month

-28.22%

3 months

-59.29%

6 months

-66.34%

Year to date

-67.42%

1 year

-86.14%

5 years

-98.28%

10 years

-99.86%

About: VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.

Employees: 14

Healthcare Biotechnology

–

Funds holding %

of 7,425 funds

–

Analysts bullish %